2019
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de la Torre PD, de Castro MDL, Millan-Ruiz Y, Sanchez-Frias M, Guil-Luna S. Red and White Wine Lees Show Inhibitory Effects on Liver Carcinogenesis. MOLECULAR NUTRITION & FOOD RESEARCH. 2019. 63. 9. DOI:10.1002/mnfr.201800864.
IF: 5,151
D: 1
Penarando J, Aranda E, Rodriguez-Ariza A. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response. TRANSLATIONAL RESEARCH. 2019. 210. 99-108. DOI:10.1016/j.trs1.2019.03.003.
IF: 4,915
D: 1
Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Gravalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, Lopez C, Alonso B, de Mena IR, Diaz-Rubio E, Tabernero J, Aranda E. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. BRITISH JOURNAL OF CANCER. 2019. 121. 5. 378-383. DOI:10.1038/s41416-019-0537-z.
IF: 5,416
Q: 1
Lopez-Sanchez LM, Jimenez-Izquierdo R, Penarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Diaz C, Ortea I, De la Haba-Rodriguez JR, Aranda E, Rodriguez-Ariza A. SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. . 0. DOI:10.1111/jcmm.14693.
IF: 4,658
Q: 1
Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Alfonso PG, Falco E, Reboredo M, Cano T, Gallego J, Vieitez JM, Layos L, Salud A, Polo E, Dotor E, Duran-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC CANCER. 2019. 19. DOI:10.1186/s12885-019-5753-7.
IF: 2,933
Q: 3
Gomez-Espana MA, Gallego J, Gonzalez-Flores E, Maurel J, Paez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). CLINICAL & TRANSLATIONAL ONCOLOGY. 2019. 21. 1. 46-54. DOI:10.1007/s12094-018-02002-w.
IF: 2,441
Q: 3
Valverde A, Ciria R, Caballero-Villarraso J, Aguilar-Melero P, Ferrin G, Ranchal I, Linares C, Herencia C, Gonzalez-Rubio S, de la Mata M, Naranjo A, Briceno J. Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. 2019. 19. 11. 1388-1398. DOI:10.2174/1871520619666190417162409.
IF: 2,18
Q: 3
Ciruelos E, Perez-Garcia JM, Gavila J, Rodriguez A, de la Haba-Rodriguez J. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept. CLINICAL DRUG INVESTIGATION. 2019. 39. 7. 595-606. DOI:10.1007/s40261-019-00790-9.
IF: 1,918
Q: 3
2018
Abad A, Martinez-Balibrea E, Vieitez JM, Alonso-Orduna V, Alfonso PG, Manzano JL, Massuti B, Benavides M, Carrato A, Zanui M, Gallego J, Gravalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. ANNALS OF ONCOLOGY. 2018; 29(2):439-444.
IF: 13,926
Q: 1 D: 1
Penarando J, Lopez-Sanchez LM, Mena R, Guil-Luna S, Conde F, Hernandez V, Toledano M, Gudino V, Raponi M, Billard C, Villar C, Diaz C, Gomez-Barbadillo J, De la Haba-Rodriguez J, Myant K, Aranda E, Rodriguez-Ariza A. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer. BMC BIOLOGY. 2018; 16:Núm artículo 3
IF: 5,77
Q: 1 D: 1
Aranda E, Garcia-Alfonso P, Benavides M, Ruiz AS, Guillen-Ponce C, Safont MJ, Alcaide J, Gomez A, Lopez R, Manzano JL, Urena MM, Sastre J, Rivera F, Gravalos C, Garcia T, Martin-Valades JI, Falco E, Navalon M, Flores EG, Tapiador AMG, Munoz AML, Barrajon E, Reboredo M, Teijido PG, Viudez A, Cardenas N, Diaz-Rubio E. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. EUROPEAN JOURNAL OF CANCER. 2018; 101:263-272.
IF: 7,191
Q: 1
Garcia-Alfonso P, Benavides M, Falco E, Munoz A, Gomez A, Sastre J, Rivera F, Montagut C, Salgado M, Lopez-Ladron A, Lopez R, de Mena IR, Duran G, Aranda E. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ONCOLOGIST. 2018; 23(11):1271-e128.
IF: 5,306
Q: 1
Alsina M, Rivera F, Ramos FJ, Galan M, Lopez R, Garcia-Alfonso P, Ales-Martinez JE, Queralt B, Anton A, Carrato A, Gravalos C, Mendez-Vidal MJ, Lopez C, de Mena IR, Tabernero J, Giralt J, Aranda E. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. TARGETED ONCOLOGY. 2018; 13(1):69-78.
IF: 3,877
Q: 2
De La Rochere P, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized Mice for the Study of Immuno-Oncology. TRENDS IN IMMUNOLOGY. 2018; 39(9):748-763.
IF: 14,188
Q: 1 D: 1
Gravalos C, Carrato A, Tobena M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limon ML, Safont MJ, de Castro EM, Garcia-Alfonso P, Aranda E. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer. CLINICAL COLORECTAL CANCER. 2018; 17(2):E323-E329.
IF: 3,861
Q: 2
Munoz AP, Garcia JMC, Rubio MDT, Vicente AMG, Pardo FJP, Londono GAJ, Castrejon AS, Aguilar EA. Value of [F-18]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. MEDICINE; 2018:97(17):Núm artículo e0098
IF: 2,028
Q: 2
Mendez-Vidal MJ, Molina A, Anido U, Chirivella I, Etxaniz O, Fernandez-Parra E, Guix M, Hernandez C, Lambea J, Montesa A, Pinto A, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC PHARMACOLOGY & TOXICOLOGY. 2018; 19:Núm artículo 77
IF: 1,865
Q: 3
Munoz AP, Garcia JMC, Rubio PT, Vicente AMG, Garcia BG, Guardia MEB, Castrejon AS, Aguilard EA. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer. MEDICINA CLINICA. 2018; 151(3):97-102.
IF: 1,168
Q: 3
Lopez RL, Herrero CC, Khosravi-Shahi P, Porta VG, Mena AC, Garcia-Foncillas J, Hernandez JJC, Vilaplana PG, Torres AA, Diaz-Rubio E, Saus MF, Aguilar EA. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(5):613-618.
IF: 2,392
Q: 3
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. JOURNAL OF CLINICAL ONCOLOGY. 2018; 36(28):2826-2835.
IF: 26,303
Q: 1 D: 1
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018; 110(6):638-648.
IF: 11,238
Q: 1 D: 1
Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 103:205-213.
IF: 7,191
Q: 1
van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. EUROPEAN JOURNAL OF CANCER. 2018; 91:99-106.
IF: 7,191
Q: 1
Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, Lopez R, Muinelo-Romay L, Montagut C, Anton A, Lopez G, Diaz-Rubio E, Rojo F, Vivancos A. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. BRITISH JOURNAL OF CANCER. 2018; 119(12):1464-1470.
IF: 5,922
Q: 1
Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuno FM, Guillen-Ponce C, Rojas I, Arande E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLOS ONE. 2018; 13(4):Núm artículo e0194844
IF: 2,766
Q: 1
Arriola E, Gomez RG, Diz P, Majem M, Aguillo MM, Valdivia J, Paredes A, Sanchez-Torres JM, Munoz SP, Barneto I, Gutierrez V, Santiago JMA, Aparisi F, Isla D, Ponce S, Baz DV, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC CANCER 2018; 18:Núm artículo 106
IF: 3,288
Q: 2
Arjona-Sanchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martin VC, Garcia-Fadrique A, Gutierrez-Calvo A, Morales R, Ortega-Perez G, Perez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sanchez-Hidalgo JM, Casado-Adam A, Garcia-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Diaz-Lopez C, Torres-Tordera E, Briceno-Delgado FJ, Rufian-Pena S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC CANCER. 2018; 18:Núm artículo 183
IF: 3,288
Q: 2
Castellano D, Maroto JP, Espinosa E, Grande E, Bolos MV, Llinares J, Esteban E, del Alba AG, Climent MA, Arranz JA, Mendez MJ, Parra EF, Anton-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, Donas JG. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. EXPERT OPINION ON DRUG SAFETY. 2018; 17(6):573-579.
IF: 3,156
Q: 2
Caries J, Castellano D, Mendez-Vidal MJ, Mellado B, Saez MI, del Alba AG, Perez-Gracia JL, Jimenez J, Suarez C, Sepulveda JM, Manneh R, Porras I, Lopez C, Morales-Barrera R, Arranz JA. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. CLINICAL GENITOURINARY CANCER. 2018; 16(6):E1133-E1139.
IF: 2,539
Q: 2
Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cadenas-Rebollo JM, Garcia-Garcia A, Gil-Ibanez B, Juan-Fita MJ, Patrono MG. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(10):1337-1344.
IF: 2,392
Q: 3
Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, Sepulveda-Sanchez JM, Campayo M, Chirivella-Gonzalez I, Garcia-del-Muro X, Gonzalez-Del-Alba A, Grande E, Suarez C. SEOM clinical guideline for treatment of kidney cancer (2017). CLINICAL & TRANSLATIONAL ONCOLOGY. 2018; 20(1):47-56.
IF: 2,392
Q: 3
Carles J, Mendez MJ, Pinto A, Saez MI, Arranz JA, Maroto P, Lopez-Criado P, Mellado B, Donas JG, Hernando S, Leon L, del Alba AG, Lainez N, Esteban E, Reynes G, Perez-Gracia JL, Germa JR, Lopez-Brea M, Perez-Valderrama B, Moretones C, Castellano D. Radium-223 international early access program: results from the Spanish subset. FUTURE ONCOLOGY. 2018; 14(1):41-50.
IF: 2,369
Q: 3
Garcia-Borruel MM, Molina AJH, Peralvarez MLR, Rincon EM, Medrano IP, Ruiz FJS, Juanena LLC, Navarro MP, Rodriguez AN, Pastor CV. Post-colonoscopy colorectal cancer: Characteristics and predictive factors. MEDICINA CLINICA. 2018; 150(1):1-7.
IF: 1,168
Q: 3
2017
Irigoyen A, Gallego J, Ponce CG, Vera R, Iranzo V, Ales I, Areevalo S, Pisa A, Martin M, Salud A, Falco E, Saenz A, Mozo JLM, Pulido G, Galaan JM, Pazo-Cid R, Rivera F, Garcia TG, Serra O, Parra EMF, Hurtado A, Reina MJG, Gomez LJL, Esther MOW, Benavides M, Aranda E, Spanish Cooperative Grp Treatment. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. EUROPEAN JOURNAL OF CANCER. 2017.7:73-82.
IF: 6,029
Q: 1
Valverde A, Penarando J, Canas A, Lopez-Sanchez LM, Conde F, Guil-Luna S, Hernandez V, Villar C, Morales-Estevez C, de la Haba-Rodriguez J, Aranda E, Rodriguez-Ariza A. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-beta-catenin signaling axis. ONCOTARGET. 2017.8(13):21754-21769.
IF: 5,168
Q: 1
Luque RM, Lopez-Sanchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-Garcia M, Alvarez-Benito M, Lopez-Miranda J, Gahete MD, Castano JP. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. ONCOTARGET. 2017.8(46):81462-81474.
IF: 5,168
Q: 1
Lopez-Sanchez LM, Jurado-Gamez B, Feu-Collado N, Valverde A, Canas A, Fernandez-Rueda JL, Aranda E, Rodriguez-Ariza A. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY. 2017.313(4):L664-L676.
IF: 4,281
Q: 1
Fernandez-Bedmar Z, Anter J, Alonso-Moraga A, de las Mulas JM, Millan-Ruiz Y, Guil-Luna S. Demethylating and anti-hepatocarcinogenic potential of hesperidin, a natural polyphenol of Citrus juices. MOLECULAR CARCINOGENESIS. 2017.56(6):1653-1662.
IF: 4,185
Q: 2
Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, De la Haba-Rodriguez J. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(12):1454-1461.
IF: 2,353
Q: 3
Aranda E, Aparicio J, Bilbao JI, Alfonso PG, Maurel J, Rodriguez J, Sangro B, Vieitez JM, Feliu J. Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. FUTURE ONCOLOGY. 2017.13(23):2065-2082.
IF: 2,131
Q: 3
Perez MJR. Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer. CASE REPORTS IN ONCOLOGY. 2017.10(2):433-437.
IF: n/a
Grasselli J, Elez E, Caratu G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Vieitez JM, Paez D, Falco E, Lopez CL, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. ANNALS OF ONCOLOGY. 2017.28(6):1294-1301.
IF: 11,855
Q: 1 D: 1
Garcia-Foncillas J, Alba E, Aranda E, Diaz-Rubio E, Lopez-Lopez R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. ANNALS OF ONCOLOGY. 2017.28(12):2943-2949.
IF: 11,855
Q: 1 D:1
Sartor O, Heinrich D, Mariados N, Vidal MJM, Keizman D, Karlsson CT, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Perez JMT, Wagner V, Li R, Nordquist LT. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. ANNALS OF ONCOLOGY. 2017.28(10):2464-2471.
IF: 11,855
Q: 1 D: 1
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, del Alba AG, Mellado B, Fernandez-Calvo O, Mendez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Saez MI, Puente J, Tandefelt DG, Wingate A, Dearnaley D, PREMIERE Collaborators; Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. ANNALS OF ONCOLOGY. 2017.28(7):1508-1516.
IF: 11,855
Q: 1 D: 1
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodriguez J, Arcusa A, Chacon JI, Sanchez-Rovira P, Plazaola A, Munoz M, Pare L, Parker JS, Ribelles N, Jimenez B, Bin Aiderus AA, Caballero R, Adamo B, Dowsett M, Carrasco E, Martin M, Dixon JM, Perou CM, Alba E. A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. CLINICAL CANCER RESEARCH. 2017.23(12):3035-3044.
IF: 9,619
Q: 1 D: 1
Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Jimenez-Gomez Y, Arias-de la Rosa I, Abalos-Aguilera MC, Rodriguez-Ariza A, Castro-Villegas MC, Ortega-Castro R, Segui R, Martinez C, Gonzalez-Conejero R, Rodriguez-Lopez S, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Escudero A, Barbarroja N, Lopez-Pedrera C. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. JOURNAL OF AUTOIMMUNITY. 2017.82():31-40.
IF: 7,641
Q: 1 D: 1
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. MOLECULAR CANCER THERAPEUTICS. 2017.16(9):1999-2007.
IF: 7,564
Q: 1
Carrato A, Abad A, Massuti B, Gravalos C, Escudero P, Longo-Munoz F, Manzano JL, Gomez A, Safont MJ, Gallego J, Garcia-Paredes B, Pericay C, Duenas R, Rivera F, Losa F, Valladares-Ayerbes M, Gonalez E, Aranda E, Spanish Cooperative Grp Treatment. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). EUROPEAN JOURNAL OF CANCER. 2017.81:191-202.
IF: 6,029
Q: 1 D: 1
Perez-Sanchez C, Aguirre MA, Ruiz-Limon P, Abalos-Aguilera MC, Jimenez-Gomez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernandez-del Rio L, Gonzalez-Reyes JA, Segui P, Collantes-Estevez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, Lopez-Pedrera C. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile A Randomized, Placebo-Controlled Trial.ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2017.37(10):1923-1932.
IF: 6,607
Q: 1 D: 1
Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, Gonzalez-Rivera M, Galvan P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Pare L, Alonso I, Albanell J, Vivancos A, Gonzalez A, Matito J, Gonzalez S, Fernandez P, Adamo B, Munoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. ONCOTARGET. 2017.8(13):21930-21937.
IF: 5,168
Q: 1
Puente J, Lainez N, Duenas M, Mendez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernandez M, Basterretxea L, Juan-Fita MJ, Anton L, Leon L, Lambea J, Perez-Valderrama B, Vazquez S, Suarez C, del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suarez-Paniagua B, Sanz J, Paramio JM, SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. ONCOTARGET. 2017.8(18):30410-30421.
IF: 5,168
Q: 1
del Alba AG, Arranz JA, Puente J, Mendez-Vidal MJ, Gallardo E, Grande E, Perez-Valderrama B, Gonzalez-Billalabeitia E, Lazaro-Quintela M, Pinto A, Lainez N, Piulats JM, Esteban E, Rey JPM, Garcia JA, Suarez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017.113:171-190.
IF: 4,971
Q: 1
Cebrian A, del Pulgar TG, Mendez-Vidal MJ, Gonzalvez ML, Lainez N, Castellano D, Garcia-Carbonero I, Esteban E, Saez MI, Villatoro R, Suarez C, Carrato A, Munarriz-Ferrandiz J, Basterrechea L, Garcia-Alonso M, Gonzalez-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, del Alba AG, Moreno F, Reynes G, Rodriguez-Remirez M, Boni V, Mahillo-Fernandez I, Martin Y, Viqueira A, Garcia-Foncillas J. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. SCIENTIFIC REPORTS. 2017.7-41371.
IF: 4,259
Q: 1
Capdevila J, Trigo JM, Aller J, Manzano JL, Adrin SG, Llopis CZ, Reig O, Bohn U, Cajal TRY, Duran-Poveda M, Astorga BG, Lopez-Alfonso A, Martinez JM, Porras I, Reina JJ, Palacios N, Grande E, Cillan E, Matos I, Grau JJ. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2017.177(4):309-317.
IF: 4,101
Q: 1
Braga S, Cardoso J, Andre S, Brito M, Sanchez P, Orvalho L, Salgado L, Dias S, Pereira-Leal JB, Passos-Coelho JL. Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer? CURRENT CANCER DRUG TARGETS. 2017.17(1):62-73.
IF: 2,992
Q: 3
Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Perez-Valderrama B, Calderero V, Perez-Gracia JL, Grande E, Algaba F. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. ONCOTARGETS AND THERAPY. 2017.10:4635-4642.
IF: 2,612
Q: 2
Gonzalez A, Lluch A, Aba E, Albanell J, Anton A, Alvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, Lopez-Vega JM, Martinez E, Munoz M, Pelaez I, Redondo A, Rodriguez A, Rodriguez CA, Ruiz A, Llombart A. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(5):616-624.
IF: 2,353
Q: 3
Perez-Segura P, Palacio JE, Vazquez L, Monereo S, de las Penas R, de Icaya PM, Gravalos C, Lecube A, Blasco A, Garcia-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. CLINICAL & TRANSLATIONAL ONCOLOGY. 2017.19(6):682-694.
IF: 2,353
Q: 3
Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA. Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO OPEN. 2017.2(3):-UNSP e000187.
IF: n/a
Garcia-Cabezas S, Centeno-Haro M, Espejo-Perez S, Carmona-Asenjo E, Moreno-Vega AL, Ortega-Salas R, Palacios-Eito A. Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case. WORLD JOURNAL OF CLINICAL ONCOLOGY. 2017.8(4):366-370.
IF: n/a